Cannabinoid receptor agonist 13, a novel cannabinoid agonist: First in human pharmacokinetics and safety

Drug Metabolism and Disposition

Volumn 37, Issue 4, 2009, Pages 827-833

  Gardin, Anne ^a   Kucher, Klaus ^a   Kiese, Beate ^a   Appel Dingemanse, Silke ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR AGONIST 13; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOOD INTAKE; HUMAN; LETHARGY; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE;

AREA UNDER CURVE; COHORT STUDIES; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; MALE; NAPHTHALENES; PLACEBOS; RECEPTORS, CANNABINOID;

EID: 63849298198     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024000     Document Type: Article

References (25)

1. Berman JS, Symonds C, and Birch R (2004) Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 112:299-306.
2. Busch U, Heinzel G, and Narjes H (1995) The effects of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. Eur J Clin Pharmacol 48:269-272.
3. Charman WN, Porter CJ, Mithani S, and Dressman JB (1997) Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 86:269-282.
4. Charman WN and Stella VJ (1986) Estimation of the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharmacol 34:175-178.
5. Charman WN and Stella VJ (1992) Lymphatic Transport of Drug, CRC Press, Boca Raton, FL. Collin C, Davies P, Mutiboko IK, and Ratcliffe S (2007) Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur JNeurol 14:290-296.
6. 2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 50:3851-3856.
7. Food and Drug Administration (1996) ICH-E6: Good Clinical Practice: Consolidated Guidance, Food and Drug Administration, Washington, DC. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, and James I (2001) The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92:91-100.
8. Freedman MD and Somberg JC (1991) Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol 31:1061-1069.
9. Gershkovich P and Hoffman A (2007) Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipopro-teins. Eur J Pharm Sci 32:24-32.
10. Ingwersen SH, Mant TG, and Larsen JJ (1993) Food intake increases the relative oral bioavail-ability of vanoxerine. Br J Clin Pharmacol 35:308-310.
11. Karst M, Salim K, Burstein S, Conrad I, Hoy L, and Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAm Med Assoc 290:1757-1762.
12. Lindholm A, Henricsson S, and Dahlqvist R (1990) The effect of food and bile acid administration on the relative bioavailability of cyclosporin. Br J Clin Pharmacol 29:541-548.
13. Metropolitan Life Insurance Company (1983) 1983 Metropolitan height and weight tables. Stat Bull 64:2-9.
14. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, and Sansom C (2004) Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59:440-452.
15. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611.
16. PertweeRGandRoss RA(2002)Cannabinoidreceptorsandtheirligands. ProstaglandinsLeukot Essent Fatty Acids 66:101-121.
17. Rice AS (2001) Cannabinoids and pain. Curr Opin Investig Drugs 2:399-414.
18. Max MB (2000) Cannabinoids modulate pain by multiple mechanisms of action. J Pain 1:2-14.
19. Rog DJ, Nurmikko TJ, Friede T, and Young CA (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65:812-819.
20. RosillonD, Stokis A, PoliG, AcerbiD, Lins R, andJeanbaptisteB(1998) Foodeffectontheoral bioavailability of manidipine: single dose, randomized, crossover study in healthy male subjects. Eur J Drug Metab Pharmacokinet 2:197-202.
21. Svendsen KB, Jensen TS, and Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329:253.
22. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (2002) Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Washington, DC.
23. Vree TB and Timmer CJ (1998) Enterohepatic cycling and pharmacokinetics of oestradiol in postmenopausal women. J Pharm Pharmacol 50:857-864.
24. Vree TB and van der Ven AJ (1999) Clinical consequences of the biphasic elimination kinetics for the diuretic effects of furosemide and its acyl glucuronide in humans. J Pharm Pharmacol 51:239-248.
25. World Medical Association (2000) Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects, Revised October 7, 2000, World Medical Association, Ferney-Voltaire, France.Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics